Resonant laser ionization and mass separation of 225Ac

Johnson, Jake D.; Heines, Michael; Bruchertseifer, Frank; Chevallay, E.; Cocolios, T. E.; Dockx, Kristof; Duchemin, Charlotte; Heinitz, S.; Heinke, Reinhard; Hurier, Sophie; Lambert, Laura; Leenders, Benji; Skliarova, Hanna; Stora, T.; Wojtaczka, Wiktoria

doi:10.1038/s41598-023-28299-4

Cited by 11 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the maximal extraction efficiency of actinium from this work was established as 2.1(6)%. This efficiency can be improved by changing the laser ionization scheme 29 . The maximal extraction efficiency of Ra and Fr was established as 13.8(25)% and 101(35)% respectively, in line with expectations based on their chemical nature.…”

Section: Discussionmentioning

confidence: 99%

Production study of Fr, Ra and Ac radioactive ion beams at ISOLDE, CERN

Jajčišinová,

Dockx,

et al. 2024

Preprint

View full text Add to dashboard Cite

The presented paper discusses the production of radioactive ion beams of francium, radium, and actinium from thick uranium carbide (UC x) targets at ISOLDE, CERN. This study focuses on the release curves and extractable yields of francium, radium and actinium isotopes. The ion source temperature was varied in order to study the relative contributions of surface and laser ionization to the production of the actinium ion beams. The experimental results are presented in the form of release parameters. Representative extractable yields per µC are presented for 222−231 Ac, several Ra and Fr isotopes in the mass ranges 214≤A≤233 and 205≤A≤231 respectively. The release efficiency for several isotopes of each of the studied elements was calculated by comparing their yields to the estimated in-target production rates modeled by CERN-FLUKA. The maximal extraction efficiency of actinium was calculated to be 2.1(6)% for a combination of surface ionization using a Ta ion source and resonant laser ionization using the two-step 438.58 nm, and 424.69 nm scheme.

show abstract

Section: Discussionmentioning

confidence: 99%

Production study of Fr, Ra and Ac radioactive ion beams at ISOLDE, CERN

Jajčišinová,

Dockx,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Research of Ac-225 radiopharmaceuticals is a promising direction for the development of more effective therapy with alpha emitters having far fewer side effects and fewer discomforts (Harvey, 2018;Price & Orvig, 2014;Ramogida & Orvig, 2013). While numerous clinical trials have shown that Ac-225 radiopharmaceuticals have the ability to treat advanced malignancies, (Chatterjee et al, 2023;Hope et al, 2023;Johnson et al, 2023;Li, Chyan, et al, 2021). As new agents receive FDA approval and expenses are covered by insurance coverage, the future of radio-theranostics is bright.…”

Section: Discussionmentioning

confidence: 99%

“…Actinium is the first element in the actinide series, and only its two naturally occurring isotopes, 228 Ac and 227 Ac, are found in the decay chains of 232 Th and 235 U, respectively. The most common isotope, 227 Ac, has a long half‐life of 21.7 years and decays primarily by β‐emissions (Johnson et al, 2023). A β‐emitter that is also exceptionally rare is 228 Ac.…”

Section: Introductionmentioning

confidence: 99%

“…The high proportion of prescribed activities leading to negative side effects and a loss of flexibility because of the short half-lives are most likely to contribute to the lack of applications. Both radium-223 (t 1/2 = 11 d) and radium-224 (t 1/2 = 3.6 d), which produce numerous alpha particles in their decay chains with total decay energies of roughly 30 MeV and a high linear energy transfer, possess required physical characteristics (Johnson et al, 2023). Lack of a stable organic or inorganic framework to bind radium is one of its main drawbacks (Hope et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A review of recent advancements in Actinium‐225 labeled compounds and biomolecules for therapeutic purposes

Hassan,

Bokhari,

Lodhi

et al. 2023

Chem Biol Drug Des

View full text Add to dashboard Cite

In nuclear medicine, cancers that cannot be cured or can only be treated partially by traditional techniques like surgery or chemotherapy are killed by ionizing radiation as a form of therapeutic treatment. Actinium‐225 is an alpha‐emitting radionuclide that is highly encouraging as a therapeutic approach and more promising for targeted alpha therapy (TAT). Actinium‐225 is the best candidate for tumor cells treatment and has physical characteristics such as high (LET) linear energy transfer (150 keV per μm), half‐life (t1/2 = 9.92d), and short ranges (400–100 μm) which prevent the damage of normal healthy tissues. The introduction of various new radiopharmaceuticals and radioisotopes has significantly assisted the advancement of nuclear medicine. Ac‐225 radiopharmaceuticals continuously demonstrate their potential as targeted alpha therapeutics. 225Ac‐labeled radiopharmaceuticals have confirmed their importance in medical and clinical areas by introducing [225Ac]Ac‐PSMA‐617, [225Ac]Ac‐DOTATOC, [225Ac]Ac‐DOTA‐substance‐P, reported significantly improved response in patients with prostate cancer, neuroendocrine, and glioma, respectively. The development of these radiopharmaceuticals required a suitable buffer, incubation time, optimal pH, and reaction temperature. There is a growing need to standardize quality control (QC) testing techniques such as radiochemical purity (RCP). This review aims to summarize the development of the Ac‐225 labeled compounds and biomolecules. The current state of their reported resulting clinical applications is also summarized as well.

show abstract

“…From this analysis we obtained maximal extraction efficiency of Ac equal to 2.1(6)%. At the offline CERN MEDICIS facility, laser ionization of actinium originating from an actinium nitrate mass marker deposited on a rhenium surface and on a ThO 2 matrix reached 15.1(6)% 30 . The conditions were substantially different between those offline measurements and the experiment reported here, in particular the absence of diffusion through the target material.…”

Section: Release Curves and Yieldsmentioning

confidence: 99%

Production study of Fr, Ra and Ac radioactive ion beams at ISOLDE, CERN

Jajčišinová,

Dockx,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The presented paper discusses the production of radioactive ion beams of francium, radium, and actinium from thick uranium carbide (UC$$_{x}$$ x ) targets at ISOLDE, CERN. This study focuses on the release curves and extractable yields of francium, radium and actinium isotopes. The ion source temperature was varied in order to study the relative contributions of surface and laser ionization to the production of the actinium ion beams. The experimental results are presented in the form of release parameters. Representative extractable yields per $$\mu$$ μ C are presented for $$^{222-231}$$ 222 - 231 Ac, several Ra and Fr isotopes in the mass ranges 214$$\le$$ ≤ A$$\le$$ ≤ 233 and 205$$\le$$ ≤ A$$\le$$ ≤ 231 respectively. The release efficiency for several isotopes of each of the studied elements was calculated by comparing their yields to the estimated in-target production rates modeled by CERN-FLUKA. The maximal extraction efficiency of actinium was calculated to be 2.1(6)% for a combination of surface ionization using a Ta ion source and resonant laser ionization using the two-step 438.58 nm, and 424.69 nm scheme.

show abstract

Resonant laser ionization and mass separation of 225Ac

Cited by 11 publications

References 56 publications

Production study of Fr, Ra and Ac radioactive ion beams at ISOLDE, CERN

Production study of Fr, Ra and Ac radioactive ion beams at ISOLDE, CERN

A review of recent advancements in Actinium‐225 labeled compounds and biomolecules for therapeutic purposes

Production study of Fr, Ra and Ac radioactive ion beams at ISOLDE, CERN

Contact Info

Product

Resources

About